Fact sheet |

Fact sheet: Gilead's chronic hepatitis C treatment restrictions

Photograph by MSF

Médecins Sans Frontières/Doctors Without Borders (MSF) plans to start treating people infected with hepatitis C virus in nine countries.

This requires affordable access to direct acting antiviral treatments, including those first registered by Gilead Sciences, and is looking for quality-assured generic versions that can help scale up treatment. However, Gilead's voluntary license restricts access to affordable generic versions for millions of people with hepatitis C in middle-income countries.